Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic bone marrow-derived mesenchymal stromal cells (Catherine Bollard)
- Development stage
- Unknown
- Lead developer
- Catherine Bollard
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of allogeneic mesenchymal stromal cells (MSCs) derived from donor bone marrow. Developed by Catherine Bollard and evaluated at the Children's National Research Institute, the therapy is currently in Phase 1 clinical trials for pediatric and young adult patients with moderate-to-severe Crohn's disease or ulcerative colitis who have failed conventional biologic therapies. The MSCs are cultured in an automated system and administered intravenously in a fresh, replicating stage of growth. These cells possess potent immunomodulatory properties, including the ability to migrate to sites of inflammation, suppress pro-inflammatory cytokine production, and promote tissue repair and regeneration without triggering immune rejection.
- Other names
- allogeneic MSCsdonor bone marrow mesenchymal stromal cellsallogeneic bone marrow-derived mesenchymal stromal cells (Catherine Bollard)
Beyond the preview
Go deeper on allogeneic bone marrow-derived mesenchymal stromal cells (Catherine Bollard).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic bone marrow-derived mesenchymal stromal cells (Catherine Bollard).